WIZP - Wize Pharma, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.9900
-0.0100 (-1.00%)
As of 9:43AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close1.0000
Open0.9900
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.9900 - 0.9900
52 Week Range0.7200 - 6.1000
Volume12,500
Avg. Volume2,076
Market Cap8.378M
Beta (3Y Monthly)0.79
PE Ratio (TTM)N/A
EPS (TTM)-0.50
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Wize Pharma Announces Meeting Its Phase II Study Primary Objective to Demonstrate LO2A Effectively Treats Dry Eye Syndrome in Patients with Conjunctivochalasis
    PR Newswire23 days ago

    Wize Pharma Announces Meeting Its Phase II Study Primary Objective to Demonstrate LO2A Effectively Treats Dry Eye Syndrome in Patients with Conjunctivochalasis

    HOD HASHARON, Israel, Nov. 20, 2018 /PRNewswire/ -- Wize Pharma, Inc. (WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced top line results from its Phase II clinical trial in Israel of LO2A for the symptomatic treatment of dry eye syndrome (DES) in patients with moderate to severe conjunctivochalasis (CCh).

  • Wize Pharma, Inc. Announces Closing of $4.45 Million Private Placement
    PR Newswire2 months ago

    Wize Pharma, Inc. Announces Closing of $4.45 Million Private Placement

    HOD HASHARON, Israel , Oct. 24, 2018 /PRNewswire/ -- Wize Pharma, Inc. ("Wize Pharma" or the "Company") (OTCQB: WIZP) a clinical-stage biopharmaceutical company focused on the treatment ...

  • Wize Pharma, Inc. Announces $4.45 Million Private Placement
    PR Newswire2 months ago

    Wize Pharma, Inc. Announces $4.45 Million Private Placement

    HOD HASHARON, Israel , Oct 23, 2018 /PRNewswire/ -- Wize Pharma, Inc. ("Wize Pharma" or the "Company") (OTCQB: WIZP) a clinical-stage biopharmaceutical company focused on the treatment ...

  • Wize Pharma Appoints Ellen Lubman to its Advisory Board
    PR Newswire3 months ago

    Wize Pharma Appoints Ellen Lubman to its Advisory Board

    HOD HASHARON, Israel, Sept. 12, 2018 /PRNewswire/ --  Wize Pharma, Inc. (WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced the appointment of Ellen A. Lubman to its Advisory Board. Ms. Lubman, a biotech executive specializing in business development, asset acquisitions and strategic partnering, will serve as a strategic advisor to Wize's senior management and Board of Directors.

  • Wize Pharma Announces Appointment of Dr. Penny Asbell, Key Opinion Leader in Dry Eye Syndrome to Advisory Board
    PR Newswire5 months ago

    Wize Pharma Announces Appointment of Dr. Penny Asbell, Key Opinion Leader in Dry Eye Syndrome to Advisory Board

    HOD HASHARON, Israel, July 26, 2018 /PRNewswire/ -- Wize Pharma, Inc. (WIZP) (the "Company" or "Wize"), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced that Dr. Penny Asbell, a leading key opinion leader in the treatment of dry eye syndrome has joined the Company's Advisory Board. As a principal investigator in countless clinical studies sponsored by the National Institute of Health's National Eye Institute and by industry sponsors, Dr. Asbell has participated in the development of pharmaceuticals that have included pivotal treatments for ocular conditions including dry eyes.

  • Wize Pharma Signs Distribution Agreement in China for LO2A
    PR Newswire6 months ago

    Wize Pharma Signs Distribution Agreement in China for LO2A

    HOD HASHARON, Israel, June 5, 2018 /PRNewswire/ -- Wize Pharma, Inc. (WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced that it has signed an exclusive distribution agreement with HPGC Medical Co., Ltd. (HPGC) for the distribution in China by HPGC of a formula known as LO2A, a drug developed for the treatment of dry eye syndrome (DES), and other ophthalmological illnesses, including Conjunctivochalasis (CCH) and Sjögren's syndrome (Sjögren's). HPGC is a division of Harbin Pharmaceutical Group Co. Ltd., one of China's largest healthcare companies with 20,000 employees and assets worth $2.9 billion.

  • Wize Pharma Announces Presentation of New Data on LO2A in the Treatment of Dry Eye Syndrome in Patients with Sjögren's Syndrome
    PR Newswire7 months ago

    Wize Pharma Announces Presentation of New Data on LO2A in the Treatment of Dry Eye Syndrome in Patients with Sjögren's Syndrome

    The poster presentation titled, "The anti-inflammatory effect of isotonic glycerol in Sjögren's syndrome-related dry eye" was delivered by Dr. Huba J. Kiss and presented findings from a study conducted by him at the Department of Ophthalmology, Semmelweis University, in Budapest, Hungary.

  • Wize Pharma to Present at 3rd Annual Disruptive Growth & Healthcare Conference in New York City on May 8, 2018
    PR Newswire7 months ago

    Wize Pharma to Present at 3rd Annual Disruptive Growth & Healthcare Conference in New York City on May 8, 2018

    HOD HASHARON, Israel, May 7, 2018 /PRNewswire/ -- Wize Pharma, Inc. (WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced it will present at the 3rd Annual Disruptive Growth & Healthcare Conference hosted by RHK Capital and Reed Smith on Tuesday, May 8, 2018 at 12:00 pm EST. Wize Pharma's COO, Noam Danenberg, will deliver the presentation in Room A/B and meet with investors during a follow-on Q&A session immediately following the presentation in Room 10. In addition, Mr. Danenberg will be one of four panellists on the conference's Disruptive Science Panel from 9:30am to 10:30am on May 8, 2018 in Room C/D. Panel members will discuss a number of topics relevant to investors including what makes their companies disruptive in the market, the key drivers to success, access to capital, and the role of intellectual property.

  • PR Newswire8 months ago

    Wize Pharma Completes Patient Enrollment in Phase II Study of LO2A for Treatment of Patients With CCH

    HOD HASHARON, Israel, April 4, 2018 /PRNewswire/ -- Wize Pharma, Inc. (WIZP) (WIZPD), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced it has completed enrolment of all 62 patients in its multi-center Phase II clinical trial in Israel of LO2A for the treatment of patients with moderate to severe Conjunctivochalasis (CCH). LO2A is currently approved in Israel for the treatment of dry eye syndrome (DES) and sales are expected to commence in Israel in 2018. Wize is also conducting a Phase IV clinical trial in Israel of LO2A for the symptomatic treatment of DES in patients with Sjögren's syndrome (Sjögren's).

  • PR Newswire9 months ago

    Wize Pharma Enrolls First Patient in Phase IV Study of LO2A for Symptomatic Treatment of Dry Eye Syndrome in Patients With Sjögren's Syndrome

    HOD HASHARON, Israel, March 28, 2018 /PRNewswire/ -- Wize Pharma, Inc. (WIZP) (WIZPD) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced it has enrolled the first patient in its Phase IV clinical trial in Israel for LO2A in the symptomatic treatment of dry eye syndrome (DES) in patients with Sjögren's syndrome. In addition to meeting marketing approval requirements in Israel, this study is also designed to support Wize's clinical approval pathway for LO2A for the treatment of DES in patients with Sjögren's in other markets including the U.S., China, and Ukraine.

  • PR Newswire9 months ago

    Wize Pharma Announces Dr. Joseph Tauber, Key Opinion Leader in Dry Eye, Joins Scientific Advisory Board

    Wize Pharma, Inc. (WIZP) (WIZPD) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced Dr. Joseph Tauber has joined the Company's Scientific Advisory Board. Dr. Tauber is an internationally recognized authority in the field of ocular surface diseases, including DES and meibomitis management.

  • PR Newswire9 months ago

    Wize Pharma Announces Reverse Stock Split Effective March 5, 2018

    HOD HASHARON, Israel, March 5, 2018 /PRNewswire/ -- Wize Pharma, Inc. (WIZP), a clinical-stage biopharmaceutical company currently focused on the treatment of ophthalmic disorders, today announced the Company's previously approved 1-for-24 reverse split of its common stock will take effect upon the opening of the market on Monday, March 5, 2018. Each 24 shares of issued and outstanding common stock will be converted into 1 share of common stock. The Company's split-adjusted common stock will trade under the ticker symbol "WIZPD" for 20 days, after which time the "D" will be removed and the stock will resume trading under the ticker symbol "WIZP".

  • PR Newswire9 months ago

    Wize Pharma Announces Expected Exercise of Investment Rights and Warrants for Total Proceeds of $1.14 Million

    Wize Pharma, Inc. (WIZP) ("Wize"), a clinical-stage biopharmaceutical company currently focused on the treatment of ophthalmic disorders, today announced it has received notices from existing stockholders and lenders to exercise investment rights and warrants to purchase an aggregate of 18,927,781 shares of common stock. The total proceeds to Wize from the exercise is expected to be approximately $1.14 million.  Wize expects that it shall receive the aggregate exercise price and issue the underlying shares of common stock in the coming weeks. A portion of the proceeds will be used to help fund our clinical studies that are evaluating the efficacy of LO2A in the treatment of dry eye syndrome in people with Sjögren's syndrome and conjunctivochalasis (CCh)," stated Wize's Chairman, Ron Mayron.

  • PR Newswire10 months ago

    Wize Pharma Receives IRB Approval of Phase IV Study Protocol for LO2A in Symptomatic Treatment of Dry Eye Syndrome in Patients With Sjögren's Syndrome

    HOD HASHARON, Israel, Feb. 20, 2018 /PRNewswire/ -- Wize Pharma, Inc. (WIZP), a clinical-stage biopharmaceutical company currently focused on the treatment of ophthalmic disorders, today announced it has received Institutional Review Board (IRB) approval for the protocol of its planned Phase IV study. This will be a Phase IV randomized, double-blind, placebo-controlled study of LO2A versus Alcon's Systane® Ultra UD, an over-the-counter lubricant eye drop product used to relieve dry and irritated eyes.